Galera Therapeutics, Inc.
GRTX
$0.0215
$0.00010.47%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.06M | 9.78M | 11.00M | 11.29M | 12.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.47M | 11.54M | 14.15M | 17.71M | 25.05M |
| Operating Income | -8.47M | -11.54M | -14.15M | -17.71M | -25.05M |
| Income Before Tax | -13.38M | -16.37M | -19.16M | -19.82M | -29.11M |
| Income Tax Expenses | -203.00K | -203.00K | -203.00K | -203.00K | -- |
| Earnings from Continuing Operations | -13.18 | -16.17 | -18.96 | -19.61 | -29.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.18M | -16.17M | -18.96M | -19.61M | -29.11M |
| EBIT | -8.47M | -11.54M | -14.15M | -17.71M | -25.05M |
| EBITDA | -8.45M | -11.52M | -14.13M | -17.47M | -24.81M |
| EPS Basic | -0.22 | -0.28 | -0.35 | -0.36 | -0.59 |
| Normalized Basic EPS | -0.07 | -0.11 | -0.15 | -0.20 | -0.34 |
| EPS Diluted | -0.22 | -0.28 | -0.35 | -0.36 | -0.59 |
| Normalized Diluted EPS | -0.07 | -0.11 | -0.15 | -0.20 | -0.34 |
| Average Basic Shares Outstanding | 306.76M | 262.64M | 218.53M | 217.56M | 208.65M |
| Average Diluted Shares Outstanding | 306.76M | 262.64M | 218.53M | 217.56M | 208.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |